目的 探討塞來昔布聯(lián)合卡培他濱節(jié)拍化療治療老年患者晚期結(jié)腸癌的臨床療效。方法 回顧性研究35例老年晚期結(jié)腸癌病例，所有患者均給予口服卡培他濱500 mg，2次/d，塞來昔布200 mg，2次/d，連續(xù)服藥直至病情進(jìn)展，至少2月后評價療效以及毒副反應(yīng)。結(jié)果 治療總有效率為37.1%，疾病控制率為77.1%，生活質(zhì)量總改善率82.9%，中位疾病進(jìn)展時間為8個月，中位生存期為14個月。所有患者均以Ⅰ、Ⅱ級毒副反應(yīng)為主，主要為白細(xì)胞減少、手足綜合征、惡心嘔吐、腹瀉、食欲減退等。結(jié)論 塞來昔布聯(lián)合卡培他濱節(jié)拍化療治療老年晚期結(jié)腸癌具有安全、有效、毒副反應(yīng)小以及患者依從性好等優(yōu)點。

Objective To explore the clinical effect of metronomic chemotherapy with celecoxib and capecitabine in aged patients with advanced colon cancer. Methods The aged patients (35 cases) with advanced colon cancer were studied retrospectively. They were po received capecitabine (500 mg) and celecoxib (200 mg) twice daily until the disease appeared progressive. The efficacy and toxicity were evaluated at least two months after therapy. Results The total effective rate was 37.1%, the disease control rate was 77.1%, the life quality improvement rate was 82.9%, the median time to progression was 8 months, and the median period to survival was 14 months. The patients mainly had I and II side effects, such as leucopenia, hand-food syndrome, nausea, vomiting, diarrhea, and loss of appetite. Conclusion Metronomic chemotherapy with celecoxib and capecitabine in aged patients with advanced colon cancer is effective and safe, at the same time the patients could tolerate metronomic chemotherapy well with little side effect.